Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171184 · ClinicalTrials.gov registry record · Phase 4
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
A Phase 4 study of Overactive Bladder, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT00171184 is a Phase 4 study of Overactive Bladder that has completed, run by Novartis. The registered enrollment target is 400 participants, above the 203-participant average among 45 other Overactive Bladder trials with a reported enrollment target (97% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00171184, a Phase 4 study of Overactive Bladder, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Darifenacin
Study Locations (1)
Texas
- Scott Department of Urology Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171184
The ClinicalTrials.gov registry entry for NCT00171184 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 45 other Overactive Bladder trials with a reported enrollment target (97% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00171184 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00171184 about?
NCT00171184 is a clinical study titled "Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder". The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.
What is the current status of trial NCT00171184?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2005-04. Estimated completion is 2006-06.
What conditions does trial NCT00171184 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT00171184?
The interventions under investigation include: Placebo (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00171184?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171184 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
RECRUITING · Phase 4
-
Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
RECRUITING · Phase 4
-
TReating Incontinence for Underlying Mental and Physical Health
RECRUITING · Phase 4
-
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
COMPLETED · Phase 4
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.